We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Call for More Clinical Trial Flexibility in Alzheimer’s Drug Guidance
Drugmakers Call for More Clinical Trial Flexibility in Alzheimer’s Drug Guidance
The FDA’s guidance on developing Alzheimer’s drugs is overly rigid when it comes to enrollment of patients in clinical trials, drugmakers said in public comments.